Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Incyte announced that the European Commission has granted marketing authorization for Opzelura (ruxolitinib) cream, marking it as the first approved treatment for repigmentation in non-segmental vitiligo within the European Union.
This approval is based on positive Phase 3 trial results showing substantial improvements in facial and total body repigmentation with the treatment. Approximately 29.8% and 30.9% of patients achieved a 75% improvement in facial vitiligo after 24 weeks of treatment. The cream is designated for use in adults and adolescents aged 12 and older, addressing a significant unmet need for patients suffering from this chronic autoimmune disease.
No serious treatment-related side effects were reported, although acne at the application site was noted as a common reaction.
Incyte has announced its participation in two key investor conferences in May 2023. The company will present at the Bank of America 2023 Health Care Conference on May 10, 2023, at 10:40 a.m. (PDT), and at the 2023 RBC Capital Markets Global Healthcare Conference on May 16, 2023, at 10:30 a.m. (EDT). Both presentations will be available via live webcast at Investor.Incyte.com and can be replayed for 30 days following the events. Incyte, based in Wilmington, Delaware, specializes in developing proprietary therapeutics to address serious unmet medical needs.
MorphoSys and Incyte presented final five-year follow-up data from the Phase 2 L-MIND study at the American Association for Cancer Research Annual Meeting 2023. The study focused on the effectiveness of Monjuvi, an immunotherapy, combined with lenalidomide, in treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Key findings included an overall response rate of 57.5%, with a complete response in 41.2% of patients. Importantly, the median overall survival was reported at 33.5 months. No new safety concerns arose, with most adverse events being grade 1 or 2. This data reinforces Monjuvi's potential as a viable treatment option for patients who are not candidates for autologous stem cell transplants.
Incyte (NASDAQ:INCY) has announced its conference call and webcast scheduled for May 2, 2023, at 8:00 a.m. ET to discuss its Q1 2023 financial results. The press release for these results will be available earlier that day at 7:00 a.m. ET. Investors can access the call via domestic and international dial-in numbers or through an online webcast at Investor.Incyte.com. A replay of the conference call will be accessible for 30 days following the event. Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware, dedicated to addressing serious unmet medical needs through the development of innovative therapeutics.
Incyte announced that the Japanese Ministry of Health, Labour and Welfare has approved Pemazyre (pemigatinib) for treating myeloid/lymphoid neoplasms (MLNs) with FGFR1 fusion. This marks a significant step in providing a treatment option for Japanese patients with this rare cancer, affecting fewer than 100 people worldwide. The approval is based on the Phase 2 FIGHT-203 study, which showed a 62.5% complete response rate among 41 patients. Pemazyre previously received Orphan Drug Designation for rare diseases. It’s also the first targeted treatment for relapsed MLNs with FGFR1 rearrangement in the U.S., showcasing Incyte's commitment to addressing critical medical needs.